- Home
- AMLX
as of 03-05-2026 3:55pm EST
$14.05
$1.00
-6.64%
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.3B | IPO Year: | 2021 |
| Target Price: | $19.56 | AVG Volume (30 days): | 774.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.53 | EPS Growth: | 65.46 |
| 52 Week Low/High: | $3.11 - $17.49 | Next Earning Date: | 06-08-2026 |
| Revenue: | $380,786,000 | Revenue Growth: | 1612.94% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -9.80 | Index: | N/A |
| Free Cash Flow: | -123481000.0 | FCF Growth: | N/A |
AI-Powered AMLX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 76.47%
76.47%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Amylyx Pharmaceuticals Inc. (AMLX)
Cohen Joshua B
Sell
Co-Chief Executive Officer
AMLX Mar 2, 2026
Avg Cost/Share
$14.48
Shares
29,282
Total Value
$424,120.49
Owned After
3,334,683
SEC Form 4
Mazzariello Gina
Sell
Chief Legal Officer
AMLX Mar 2, 2026
Avg Cost/Share
$14.52
Shares
6,844
Total Value
$99,378.30
Owned After
134,430
SEC Form 4
Klee Justin B.
Sell
Co-Chief Executive Officer
AMLX Mar 2, 2026
Avg Cost/Share
$14.47
Shares
29,282
Total Value
$423,760.32
Owned After
3,334,616
SEC Form 4
Bedrosian Camille L
Sell
Chief Medical Officer
AMLX Mar 2, 2026
Avg Cost/Share
$14.58
Shares
6,461
Total Value
$94,205.26
Owned After
169,295
SEC Form 4
FRATES JAMES M
Sell
Chief Financial Officer
AMLX Mar 2, 2026
Avg Cost/Share
$14.52
Shares
7,909
Total Value
$114,851.33
Owned After
165,638
SEC Form 4
Mazzariello Gina
Sell
Chief Legal Officer
AMLX Feb 23, 2026
Avg Cost/Share
$14.14
Shares
3,419
Total Value
$48,352.18
Owned After
134,430
SEC Form 4
Cohen Joshua B
Sell
Co-Chief Executive Officer
AMLX Feb 2, 2026
Avg Cost/Share
$14.68
Shares
15,500
Total Value
$227,592.70
Owned After
3,334,683
SEC Form 4
Mazzariello Gina
Sell
Chief Legal Officer
AMLX Feb 2, 2026
Avg Cost/Share
$14.65
Shares
3,448
Total Value
$50,515.61
Owned After
134,430
SEC Form 4
Klee Justin B.
Sell
Co-Chief Executive Officer
AMLX Feb 2, 2026
Avg Cost/Share
$14.69
Shares
15,500
Total Value
$227,617.50
Owned After
3,334,616
SEC Form 4
FRATES JAMES M
Sell
Chief Financial Officer
AMLX Feb 2, 2026
Avg Cost/Share
$14.65
Shares
3,557
Total Value
$52,096.89
Owned After
165,638
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Mar 2, 2026 | Sell | $14.48 | 29,282 | $424,120.49 | 3,334,683 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Mar 2, 2026 | Sell | $14.52 | 6,844 | $99,378.30 | 134,430 | |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Mar 2, 2026 | Sell | $14.47 | 29,282 | $423,760.32 | 3,334,616 | |
| Bedrosian Camille L | AMLX | Chief Medical Officer | Mar 2, 2026 | Sell | $14.58 | 6,461 | $94,205.26 | 169,295 | |
| FRATES JAMES M | AMLX | Chief Financial Officer | Mar 2, 2026 | Sell | $14.52 | 7,909 | $114,851.33 | 165,638 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Feb 23, 2026 | Sell | $14.14 | 3,419 | $48,352.18 | 134,430 | |
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Feb 2, 2026 | Sell | $14.68 | 15,500 | $227,592.70 | 3,334,683 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Feb 2, 2026 | Sell | $14.65 | 3,448 | $50,515.61 | 134,430 | |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Feb 2, 2026 | Sell | $14.69 | 15,500 | $227,617.50 | 3,334,616 | |
| FRATES JAMES M | AMLX | Chief Financial Officer | Feb 2, 2026 | Sell | $14.65 | 3,557 | $52,096.89 | 165,638 |
Latest Amylyx Pharmaceuticals Inc. News
AMLX Breaking Stock News: Dive into AMLX Ticker-Specific Updates for Smart Investing
Compare AMLX vs Leading Stocks
See how AMLX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AMLX Amylyx Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.